Progenity to Present at the 2021 ICR Conference
January 05, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Global Oncology Precision Medicine Market (2020 to 2030) - Analysis and Forecast
January 05, 2021 07:13 ET
|
Research and Markets
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries)- Analysis and Forecast, 2020-2030"...
Global Genetic Toxicology Testing Market Report 2020-2025 - Opportunities in Increased Focus on Drug Discovery and Personalized Medicines Using In-Vitro Methods
January 04, 2021 07:03 ET
|
Research and Markets
Dublin, Jan. 04, 2021 (GLOBE NEWSWIRE) -- The "Global Genetic Toxicology Testing Market with COVID-19 Impact Analysis by Product (Assays, Reagents & Consumables, Services), Application...
Single-cell Sequencing Services and Technologies Market, 2020-2030 - Global Current Landscape and the Future Opportunities
December 17, 2020 04:53 ET
|
Research and Markets
Dublin, Dec. 17, 2020 (GLOBE NEWSWIRE) -- The "Single-cell Sequencing Services and Technologies Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering. The 'Single-cell...
Philips and InSightec partner to expand access to MR-guided focused ultrasound for incisionless neurosurgery
December 17, 2020 04:00 ET
|
Royal Philips
December 17, 2020 Companies to develop compatibility of Philips’ MR Ingenia 3.0T and 1.5T systems with the InSightec Exablate Neuro platform Amsterdam, the Netherlands and...
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
December 15, 2020 10:00 ET
|
4D Path
NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter,...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
December 11, 2020 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
December 08, 2020 20:22 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
December 07, 2020 16:05 ET
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kura Oncology Announces Commencement of Public Offering of Common Stock
December 07, 2020 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...